InTandem Capital Partners, LLC (“InTandem Capital”), a healthcare services focused private equity firm, announced today that its affiliated funds, InTandem Capital Partners Fund II, LP and InTandem Capital Opportunities Fund, LP, have completed a majority recapitalization and combination of MPP Infusion Centers and ID Consultants, both leading providers of accessible and affordable ambulatory infusion services. The two companies will combine to create Vivo Infusion, a newly established company and brand. Financial terms of the transaction were not disclosed.
Based in Denver, Colorado, Vivo Infusion is a provider of accessible, affordable, and safe community-based infusion and injection care for patients suffering from compromised immune systems, infectious disease, and other medical conditions. Vivo Infusion provides convenient, compassionate, expert care administered in safe and inviting state-of-the-art facilities using efficient and cost-effective patient-focused best practices. Vivo currently serves communities in Colorado, Florida, Ohio, Oklahoma, and Texas with plans to expand into additional states.
“Combining these two innovative companies creates a platform to broaden our services and extend our reach to many more individuals in need of high quality care,” said Chris Reef, Chief Executive Officer of the newly formed enterprise. “Having previously been the CEO of a portfolio company managed by InTandem’s principals, I understand firsthand the depth of operating and investment expertise InTandem brings to companies like Vivo Infusion. InTandem shares our mission and vision for the future of infusion services – improving patient outcomes, delivering a better patient experience and lowering costs.”
“InTandem invests in companies that are poised to become leaders in their markets, and as we bring together two leading providers of ambulatory infusion services, we are confident that Chris and the talented leaders at the combined company are perfectly positioned to accelerate their growth potential as Vivo Infusion,” said Brad Coppens, Senior Managing Director of InTandem Capital. “Ambulatory infusion centers have emerged as a ‘sweet spot’ in the infusion market, offering a compelling value proposition to patients, referring physicians and payors. The combination of advanced clinical oversight, administrative support, labor efficiency, and cost of service advantages versus comparable inpatient, home and physician office-based settings are keys to that value proposition. Vivo Infusion’s relentless focus on patient experience aligns perfectly with our strategy and standards for partnering with healthcare services companies, and we look forward to helping the company succeed over the long-term.”
About InTandem Capital Partners
InTandem Capital Partners is a private equity firm that invests in and helps accelerate the growth of select healthcare services companies. Its goal is to build excellent businesses of significant value working collaboratively with its management team partners. InTandem is comprised of former business executives and experienced investors, and is uniquely qualified to provide strategic, acquisition and operating expertise to help companies significantly increase their value over time. InTandem provides active support to the management of its portfolio companies directly and leverages its network of industry executives to augment its capabilities. For further information, please visit: www.intandemcapital.com.
About Vivo Infusion
Vivo Infusion is a leading provider of accessible, affordable, and safe community-based infusion and injection care for patients suffering from compromised immune systems, infectious disease, and other medical conditions. Vivo Infusion provides convenient, compassionate, expert care administered in safe and inviting state-of-the-art facilities using efficient and cost-effective patient-focused best practices. Vivo currently serves communities in Colorado, Florida, Ohio, Oklahoma, and Texas with plans to expand into additional states. For more information visit vivoinfusion.com.
The M&A market for healthcare companies continues to strengthen in 2022 ahead of projected increases in US capital gains taxes. There is unprecedented capital in market, the lowest interest rates in US history and strong acquirer motivations for high quality healthcare companies. Across the continuum of care, buyers and investors are looking for well established, profitable businesses and offering strong valuations and options for management.
Do you know the current market value of your business? We do! We are here to help you plan, prepare, explore and succeed in executing your strategic options.
Contact Paragon Ventures for more information.
800-719-1555
